StablevaX™ is a novel and distruptive technology that aims to eliminate the need for refrigeration (Cold Chain), reduce vaccine wastage and save lives through better immunisation
Stablepharma appoints Özgür Tuncer, ex IQVIA & Pfizer Executive, as CEOStablepharma & BB-NCIPD Ltd ('Bul Bio') collaborating on Td vaccine
StablevaX™ - a vital complementary technology for vaccines
Our novel patented StablevaX™ technology can thermally stabilise and deliver a wide range of vaccines without the requirement for refrigeration. A stabilised vaccine solution that could eliminate the need for the cold chain and enable stockpiling anywhere in the world.
Stablepharma’s strategy is to initially target the T&D containing vaccines. We have signed an R&D and Commercial LoI with the European WHO pre-qualified vaccine manufacturer Bul Bio in order to thermo-stabilise their Tetadif (Td) vaccine.
Stablepharma also recently initiated a programme on thermostability of naked SARS-COV-2 mRNA as well as lipid nano-particle (LNP) containing the SARS-COV-2 mRNA. Our aim is to demonstrate that our novel technology StablevaX™ can stabilise the mRNA and LNP to be stored and transported in higher temperatures.
Latest Press Coverage StablevaX™
Stablepharma Technology
StablevaX™ is a patented product that aims for enhanced thermostability, following WHO protocols
Zero Refrigeration
StablevaX™ technology aims to eliminate the need for refrigeration
Thermostable Vaccines
StablevaX™ technology is designed with the aim of administering to patients without any change to current practice
Our white paper
StablevaX™ - a complementary technology for COVID-19 vaccines
In light of the ongoing Covid-19 pandemic, the challenge of equitable and efficient vaccine delivery has never appeared starker. Stablepharma believes that StablevaX™ could be a crucial complementary technology to currently available Covid-19 vaccines, especially those using mRNA-based approaches.
